CliffBio
small molecule

KHAPZORY

LEVOLEUCOVORIN

Loss of exclusivityMarch 2039latest FDA-listed patent expiry
CompanyAcrotech Biopharma →View the full company profile on CliffBio

Drug detail

Brand nameKHAPZORY
Active ingredientLEVOLEUCOVORIN
Strength175MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2018
Marketing statusRX

Listed patents

PatentExpiresType
11541012March 2039product

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KHAPZORY patent cliff — loss of exclusivity March 2039 | CliffBio